Validation and characterization of a human volunteer challenge model for cholera by using frozen bacteria of the new Vibrio cholerae epidemic serotype, O139

Infection and Immunity

Volumn 67, Issue 12, 1999, Pages 6346-6349

  Cohen, Mitchell B ^a,b   Giannella, Ralph A ^c   Losonsky, Genevieve A ^d   Lang, Dennis R ^e   Parker, Susan ^c,f   Hawkins, Jennifer A ^a,b   Gunther, Carolyn ^a,b   Schiff, Gilbert A ^c,f  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Div Pediat Gastroenterol Nutr   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Gamble Program for Clinical Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHOLERA VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CHOLERA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EPIDEMIC; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SEROTYPE; STRAIN DIFFERENCE; VIBRIO CHOLERAE;

ANTIBODIES, BACTERIAL; BLOOD GROUP ANTIGENS; CHOLERA; DISEASE OUTBREAKS; FECES; FREEZING; HUMANS; SEROTYPING; VIBRIO CHOLERAE;

EID: 0032699275     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Albert, M. J., M. Ansaruzzaman, P. K. Bardham, A. S. G. Faruque, M. S. Islam, D. Mahalanabis, R. B. Sack, M. A. Salam, A. K. Siddique, M. Yunus, and K. Zaman. 1993. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 342:387-390. (Letter.)
2. Blake, P. A. 1993. Epidemiology of cholera in the Americas. Gastroenterol. Clin. N. Am. 3:639-660.
3. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, M. R. Khan, S. Huda, F. Ahmed, J. Gomes, M. R. Rao, A.-M. Svennerholm, and J. Holmgren. 1989. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J. Infect. Dis. 159:770-773.
4. Clements, M. L., M. M. Levine, C. R. Young, R. E. Black, Y. L. Lim, R. M. Robbins-Browne, and J. P. Craig. 1982. Magnitude, kinetics and duration of the vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae O1. J. Infect. Dis. 145:465-473.
5. Glass, R. I., J. Holmgren, C. E. Haley, M. R. Khan, A. M. Svennerholm, B. J. Stoll, K. M. Belayet Hossain, R. E. Black, M. Yunus, and D. Barua. 1985. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol. 121:791-796.
6. Kaper, J. B., J. G. Morris, Jr., and M. M. Levine. 1995. Cholera. Clin. Microbiol. Rev. 8:48-86.
7. Lagos, R., A. Avenano, V. Prado, I. Horwitz, S. Wasserman, G. Losonsky, S. Cryz, Jr., J. B. Kaper, and M. M. Levine. 1995. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63:707-709.
8. Losonsky, G. A., J. Yunyongying, V. Lim, M. Reymann, Y. L. Lim, S. S. X. Wasserman, and M. M. Levine. 1996. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 64:10-15.
9. Losonsky, G. A., Y. Lim, P. Motamedi, L. E. Comstock, J. A. Johnson, J. G. Morris, Jr., C. O. Tacket, J. B. Kaper, and M. M. Levine. 1997. Clin. Diagn. Lab. Immunol. 4:264-269.
10. Morris, J. G., Jr., G. A. Losonsky, J. A. Johnson, C. O. Tacket, J. P. Nataro, P. Panigrahi, and M. M. Levine. 1995. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J. Infect. Dis. 171:903-908.
11. Pitisuttithum, P. Personal communication.
12. Qadri, F., C. Wenneras, M. J. Albert, J. Hossain, K. Mannoor, Y. A. Begum, G. Mohi, M. A. Salam, R. B. Sack, and A. M. Svennerholm. 1997. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect. Immun. 65:3571-3576.
13. Sack, D. A. Personal communication.
14. Sack, D. A., C. O. Tacket, M. B. Cohen, R. B. Sack, G. A. Losonsky, J. Shimko, J. P. Nataro, R. Edelman, M. M. Levine, R. A. Giannella, G. Schiff, and D. Lang. 1998. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect. Immun. 66:1968-1972.
15. Sanchez, J. L., and D. N. Taylor. 1997. Cholera. Lancet 349:1825-1830.
16. Tacket, C. O., G. Losonsky, J. P. Nataro, L. Comstock, J. Michalski, R. Edelman, J. B. Kaper, and M. M. Levine. 1995. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety, efficacy against experimental challenge. J. Infect. Dis. 172:883-886.
17. Tacket, C. O., M. B. Cohen, S. S. Wasserman, G. Losonsky, S. Livio, K. Kotloff, R. Edelman, J. B. Kaper, S. J. Cryz, R. A. Giannella, G. Schiff, D. R. Lang, and M. M. Levine. 1999. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 E1 Tor lnaba three months after vaccination. Infect. Immun. 67:6341-6345.